Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | RGS12 | O14924 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18943970 | 1.00 | KDM4E (0.57) | KDM4EALDH1A1ADRA2CLMNAADRA2A | |
| SCHEMBL359794 | 1.00 | KDM4E (0.57) | KDM4EALDH1A1ADRA2CLMNAADRA2A | |
| SCHEMBL28075639 | 1.00 | KDM4E (0.57) | KDM4EALDH1A1ADRA2CLMNAADRA2A | |
| SCHEMBL4186259 | 1.00 | KDM4E (0.57) | KDM4EALDH1A1ADRA2CLMNAADRA2A | |
| SCHEMBL9682746 | 1.00 | KDM4E (0.57) | KDM4EALDH1A1ADRA2CLMNAADRA2A | |
| SCHEMBL7125858 | 0.87 | KDM4E (0.46) | KDM4EALDH1A1ADRA2CLMNAADRA2A | |
| SCHEMBL10255083 | 0.82 | AOC3 (0.58) | KDM4EALDH1A1ADRA2CLMNAADRA2A | |
| SCHEMBL14388207 | 0.82 | AOC3 (0.58) | KDM4EALDH1A1ADRA2CLMNAADRA2A | |
| SCHEMBL14387920 | 0.82 | AOC3 (0.58) | KDM4EALDH1A1ADRA2CLMNAADRA2A | |
| SCHEMBL4828396 | 0.82 | AOC3 (0.58) | KDM4EALDH1A1ADRA2CLMNAADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023191951-A1 | SMALL MOLECULE ALLOSTERIC MODULATORS OF THE SEROTONIN (5-HT) 5-HT2C AND 5-HT2A RECEPTORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11708371-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20180065973-A1 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | MERCK SHARP & DOHME CORP. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9822121-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160176884-A1 | Process for Making Beta 3 Agonists and Intermediates | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | US | disclosed |
| US-20150087832-A1 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | MERCK SHARP & DOHME, CORP. (US) | 2015-03-26 | — | — | US | disclosed |
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | SHIONOGI & CO., LTD. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | SHIONOGI & CO., LTD. (JP) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | CNR2, CNR1, OPRM1 | KDM4E 2957/4885ALDH1A1 2784/4885ADRA2C 182/4885 |
| US-20160176884-A1 | Process for Making Beta 3 Agonists and Intermediates | ADRB3, ADRB2, ADRB1 | KDM4E 4201/4885ALDH1A1 293/4885ADRA2C 7/4885 |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | KDM4E 1679/4885ALDH1A1 3078/4885ADRA2C 117/4885 |
| US-20150087832-A1 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | ADRB3, ADRB2, ADRB1 | KDM4E 4201/4885ALDH1A1 293/4885ADRA2C 7/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | KDM4E 3245/4885ALDH1A1 3580/4885ADRA2C 78/4885 |
| US-20180065973-A1 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | ADRB3, ADRB2, ADRB1 | KDM4E 4201/4885ALDH1A1 293/4885ADRA2C 7/4885 |
| US-11708371-B2 | Process for making beta 3 agonists and intermediates | ADRB3, ADRB2, ADRB1 | KDM4E 4201/4885ALDH1A1 293/4885ADRA2C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.